Accelerating translational research through Cardiff University’s Clinical Innovation pipeline
Lead Research Organisation:
CARDIFF UNIVERSITY
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
Publications
Bennasar M
(2016)
Huntington's Disease Assessment Using Tri Axis Accelerometers
in Procedia Computer Science
Bennasar M
(2018)
Automated Assessment of Movement Impairment in Huntington's Disease.
in IEEE transactions on neural systems and rehabilitation engineering : a publication of the IEEE Engineering in Medicine and Biology Society
Bonnet CS
(2020)
AMPA/kainate glutamate receptor antagonists prevent posttraumatic osteoarthritis.
in JCI insight
Clinch S
(2017)
Rehabilitation training in neural restitution.
in Progress in brain research
Clinch SP
(2018)
Rethinking Functional Outcome Measures: The Development of a Novel Upper Limb Token Transfer Test to Assess Basal Ganglia Dysfunction.
in Frontiers in neuroscience
Kandil S
(2018)
The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.
in Chemical biology & drug design
Kandil SB
(2020)
Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
in Molecules (Basel, Switzerland)
Linden DE
(2016)
Real-time functional magnetic resonance imaging neurofeedback in motor neurorehabilitation.
in Current opinion in neurology
Rastogi N
(2021)
Use of an anti-CD200-blocking antibody improves immune responses to AML in vitro and in vivo.
in British journal of haematology
| Description | "Mechanical Loading in Disease (MeLoDi)" |
| Amount | £99,820 (GBP) |
| Funding ID | NC/C016103/1 |
| Organisation | National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2017 |
| End | 12/2019 |
| Description | 'Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts' |
| Amount | £127,762 (GBP) |
| Organisation | QBiotics |
| Sector | Private |
| Country | Australia |
| Start | 01/2018 |
| End | 12/2020 |
| Description | 'Repurposing ingenol mebutate as a novel pharmaceutical therapy for dermal fibrosis' |
| Amount | £49,995 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 08/2016 |
| End | 08/2017 |
| Description | Development of TheraNostic ProTides |
| Amount | £48,709 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 12/2020 |
| Description | Investigating a candidate biomarker of osteoarthritis: Role in pathogenesis and efficacy to diagnose disease. |
| Amount | £60,000 (GBP) |
| Organisation | Cardiff University |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2021 |
| Description | Life Sciences Bridging Fund |
| Amount | £51,000 (GBP) |
| Organisation | Government of Wales |
| Sector | Public |
| Country | United Kingdom |
| Start | 06/2017 |
| End | 02/2018 |
| Description | PACE-HD |
| Amount | £411,000 (GBP) |
| Organisation | Gossweiler Foundation |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 01/2018 |
| End | 01/2020 |
| Description | Role of protein kinase C (PKC) isoforms and downstream signalling pathways in mediating the anti-scarring effects of ingenol mebutate in dermal fibroblasts-myofibroblasts |
| Amount | £110,000 (GBP) |
| Organisation | Government of Kuwait |
| Sector | Public |
| Country | Kuwait |
| Start | 09/2020 |
| End | 09/2023 |
| Description | Synovial joint in vitro model that is scalable for medium throughput screening applications. |
| Amount | £51,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 04/2019 |
| Description | Validation of a stem cell derived cartilage model for osteoarthritis research and drug screening. |
| Amount | £86,000 (GBP) |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 09/2021 |
| Description | kinase selectivity panel profiling |
| Amount | £5,000 (GBP) |
| Organisation | Life Sciences Research Network Wales |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2018 |
| End | 11/2018 |
| Description | DA Bioventix |
| Organisation | Bioventix |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Currently interacting with (Bioventix, Farnham)in relation to commercialisation of our 'technology'. There is interest both in using our cartilage model as a screening platform as well as in the candidate biomarkers. |
| Collaborator Contribution | Novel mAbs |
| Impact | n/a |
| Start Year | 2018 |
| Description | DA UCB |
| Organisation | UCB Pharma |
| Department | Cellular Sciences - UCB Pharma |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | Currently interacting with (UCB Pharma, Slough) in relation to commercialisation of our 'technology'. There is interest both in using our cartilage model as a screening platform as well as in the candidate biomarkers. |
| Collaborator Contribution | Novel MAbs |
| Impact | n/a |
| Start Year | 2018 |
| Description | Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts |
| Organisation | QBiotics |
| Country | Australia |
| Sector | Private |
| PI Contribution | 'Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts'. |
| Collaborator Contribution | 'Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts'. Based on the success of our ongoing collaboration, in 2020-21, QBiotics selected Cardiff as the site for their UK subsidiary and only UK office. This is only their third ever office/subsidiary outside their Headquarters in Australia. https://opengovuk.com/company/12717887 |
| Impact | Based on the success of our ongoing collaboration, in 2020-21, QBiotics selected Cardiff as the site for their UK subsidiary and only UK office. This is only their third ever office/subsidiary outside their Headquarters in Australia. https://opengovuk.com/company/12717887 |
| Start Year | 2012 |
| Description | Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts |
| Organisation | QBiotics |
| Country | Australia |
| Sector | Private |
| PI Contribution | 'Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts'. |
| Collaborator Contribution | 'Evaluation of novel epoxy-tigliane pharmaceuticals as modulators of impaired wound healing responses in chronic wound fibroblasts'. Based on the success of our ongoing collaboration, in 2020-21, QBiotics selected Cardiff as the site for their UK subsidiary and only UK office. This is only their third ever office/subsidiary outside their Headquarters in Australia. https://opengovuk.com/company/12717887 |
| Impact | Based on the success of our ongoing collaboration, in 2020-21, QBiotics selected Cardiff as the site for their UK subsidiary and only UK office. This is only their third ever office/subsidiary outside their Headquarters in Australia. https://opengovuk.com/company/12717887 |
| Start Year | 2012 |
| Description | Leo Pharma |
| Organisation | LEO Pharma (including subsidiary Peplin Ltd) |
| Country | Denmark |
| Sector | Private |
| PI Contribution | now in the process of discussing further in vitro / ex vivo research work and funding options with LEO Pharma, to be undertaken in the foreseeable future. |
| Collaborator Contribution | Industry guidance and in kind contributions |
| Impact | n/a |
| Start Year | 2016 |
| Description | Novartis collaboration |
| Organisation | Novartis |
| Country | Global |
| Sector | Private |
| PI Contribution | REPURPOSING LICENSED DRUGS FOR TREATMENT OF INJURY-INDUCED OSTEOARTHRITS. |
| Collaborator Contribution | Key reagent is supplied free of charge under MTA with Novartis. |
| Impact | n/a |
| Start Year | 2017 |
| Description | |
| IP Reference | |
| Protection | Copyrighted (e.g. software) |
| Year Protection Granted | |
| Licensed | Yes |
| Impact | Secondary outcome measures |
| Description | 'Biological interventions for post-traumatic osteoarthritis' |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Invited speaker presentation |
| Year(s) Of Engagement Activity | 2019 |
| Description | Workshop with KOLs |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Industry/Business |
| Results and Impact | Scoping of commercial opportunities |
| Year(s) Of Engagement Activity | 2018 |